Anxiety and Depression in Primary Biliary Cholangitis: What Patients Need to Know

Table of Contents

• Key Points
• What Is Primary Biliary Cholangitis (PBC)?
• Who Gets PBC? Risk Factors and Demographics
• The Natural History of PBC: What to Expect
• The Most Common Symptoms: Fatigue and Pruritus
• How Doctors Measure Symptoms and Quality of Life
• Depression and Anxiety in Chronic Liver Disease
• Fatigue: The Most Debilitating Symptom
• Pruritus (Itching) and Sleep Disturbances
• Why Do Depression and Anxiety Occur in PBC? Possible Mechanisms
• Self-Assessment vs. Clinical Diagnosis: An Important Distinction
• Liver Transplant and Mental Health in PBC
• Medications and Therapies for Depression and Anxiety in PBC
• Limitations of Current Research
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• PBC affects mental health: fatigue, itching, sleep problems, anxiety, and depression are common and real.
• One study of 55 PBC patients found only 2 of 21 screening positive for depression met formal DSM-IV criteria.
• Fatigue is the most reported PBC symptom and is independent of liver disease severity.
• Mirtazapine was associated with lower risk of cirrhosis complications, liver transplant need, and death in a 2018 UK cohort.
• Depression in PBC is linked to poorer outcomes, so discuss mental health screening and treatment with your care team.

What Is Primary Biliary Cholangitis (PBC)?

Primary biliary cholangitis, formerly known as primary biliary cirrhosis, is a chronic autoimmune liver disease that affects the small bile ducts inside the liver. In PBC, the immune system mistakenly attacks these ducts, causing inflammation and injury. Over time, this damage can lead to a buildup of bile and toxins in the liver, which may ultimately progress to cirrhosis (severe scarring of the liver) and liver failure. Without treatment, advanced PBC can require a liver transplant or result in death.

The word "cholangitis" refers to inflammation of the bile ducts, while "primary" indicates that this inflammation is the root cause of the disease, not a consequence of another condition. Although PBC is a liver disease, its effects reach far beyond the liver — most patients experience symptoms that affect their physical, mental, emotional, and social well-being.

Two medications are currently approved for treating PBC: ursodeoxycholic acid (UDCA) and obeticholic acid (OCA). These treatments have been shown to reduce the risk of disease progression. However, even with treatment, many patients continue to experience significant symptoms — particularly fatigue and itching — that are independent of how advanced their liver disease is.

Who Gets PBC? Risk Factors and Demographics

The exact cause of PBC remains unknown, but researchers believe both genetic and environmental factors play a role. Currently, over 90% of PBC patients are women, and the majority are Caucasian over the age of 50. The disease also runs in families — an increased prevalence has been reported in identical twins and first-degree relatives (parents, siblings, or children) of PBC patients.

Geographic clustering of PBC cases suggests that environmental triggers, such as toxins or bacteria, may contribute to the development of the disease. The numbers tell a striking story about geography:

• In northern Europe, PBC affects 200 to 251 cases per million people
• In sub-Saharan Africa and India, the disease is rare

Diagnosis of PBC has become more straightforward over the years. The condition is typically diagnosed based on abnormal liver test results showing a "cholestatic pattern" (meaning bile flow is impaired) combined with the presence of disease-specific antibodies called antimitochondrial antibodies (AMA). About 95% of PBC patients test positive for AMA, meaning a liver biopsy is only needed for diagnosis in a small minority of patients.

As the disease advances, patients develop elevated levels of serum bilirubin — a yellow pigment produced by the liver — which reflects the progressive loss of intrahepatic bile ducts. Elevated levels of serum alkaline phosphatase (ALP) and/or bilirubin, even after an adequate trial of UDCA, predict an increased risk of liver-related complications and liver-related death or the need for liver transplant. These markers are used in clinical trials as surrogate markers for adverse disease outcomes and help identify patients who may benefit from OCA as a second-line treatment.

The Natural History of PBC: What to Expect

Many patients remain asymptomatic (without symptoms) for years, which can delay diagnosis. About 60% of patients today are diagnosed during this asymptomatic period, largely because diagnostic tools such as serological blood tests are now widely available. Some of these undiagnosed patients present with high cholesterol (hypercholesteremia), mild itching, or Sicca syndrome (a condition causing dry eyes and dry mouth).

PBC has several different clinical presentations. The three most common patterns include:

1. A complete lack of symptoms at diagnosis
2. A less aggressive "silent" form in which symptoms may emerge later
3. The presence of symptoms from the start

Survival rates are lower among all PBC patient groups when compared to age-matched and gender-matched control populations. However, studies have shown that patients who are asymptomatic at diagnosis have better outcomes than those who are symptomatic. Patients who are diagnosed with PBC at a younger age generally experience worse outcomes and a more intense symptom burden.

Following diagnosis and treatment with UDCA, many patients can live a normal life. However, a significant number continue to experience symptom burden that is independent of their liver disease. Patients who cannot tolerate UDCA may require other therapies, including investigational drugs.

The complications of PBC can affect the whole body, including:

• Bone disease: Between 20% and 45% of PBC patients experience osteopenia (low bone density) or osteoporosis (brittle bones), which increases the likelihood of fractures and falls
• Fat-soluble vitamin deficiency
• Hyperlipidemia (elevated fats in the blood)
• Fatigue and pruritus (itching)

Many PBC patients also have other autoimmune conditions. About 84% of PBC patients exhibit features of a non-hepatic autoimmune disease, and 40% report two or more non-hepatic diseases. One study found that 10% of PBC patients had rheumatoid arthritis, 12% had Raynaud's syndrome (a condition causing reduced blood flow to fingers and toes), and 10% had Sjogren's syndrome. The development of esophageal varices (enlarged veins in the esophagus) and hepatocellular carcinoma (liver cancer) can also affect the trajectory of PBC and survival.

The Most Common Symptoms: Fatigue and Pruritus

Many patients report that the two most common symptoms of PBC — fatigue and pruritus (itching) — can be debilitating and interfere with their ability to complete daily functions. This intense symptom burden leads many patients to self-report depressive symptoms, anxiety, and an overall lower health-related quality of life.

Symptomatic patients and patients diagnosed earlier in life usually experience greater psychological, social, and physical symptom burden, which further negatively impacts their perceived quality of life. Mental health disorders are more common in patients with chronic disease, and this can negatively affect the trajectory of the disease itself. For this reason, evaluating mental health is an important aspect of care for clinicians treating PBC patients.

How Doctors Measure Symptoms and Quality of Life

Symptom burden and quality of life in PBC patients are primarily monitored through self-assessments and interviews. A variety of standardized surveys are used to quantify health-related quality of life, anxiety, depressive symptoms, sleep quality, fatigue, and itching. The most widely used survey specific to PBC is the PBC-40, a collection of 40 questions that address various physical, social, and psychological factors affecting patients' health-related quality of life.

Other important tools used in research and clinical practice include:

• Hospital Anxiety and Depression Scale (HADS): A self-assessment administered to outpatients to evaluate whether they have anxiety or depression and how severe it is
• Beck Depression Inventory (BDI): A 21-question self-assessment used to evaluate and scale depressive symptoms as outlined by the Diagnostic and Statistical Manual for Mental Disorders
• Penn State Worry Questionnaire (PSWQ): A 16-item questionnaire used to evaluate generalized anxiety disorder
• Visual Analogue Scale (VAS): A 10cm scale used to measure disease-related pain, ranging from no pain to severe pain
• Fisk Fatigue Severity Scale (FFSS): A self-reported measurement of disease-related physical, social, and cognitive fatigue
• Epworth Sleepiness Scale (ESS): An eight-question self-assessment used to evaluate excessive daytime sleepiness
• Hamilton Rating Scale for Depression (HRSD): A 17-question survey used to evaluate depression severity
• Center for Epidemiologic Studies Depression Rating Scale (CES-D): A 20-question self-assessment measuring depressive symptoms
• Short Form-36 Health Survey (SF-36): A 36-item questionnaire used to evaluate overall health-related quality of life
• Symptom Checklist-90 (SCL-90): A questionnaire evaluating 90 distress symptoms across nine psychological domains

Depression and Anxiety in Chronic Liver Disease

Depression and anxiety are common among patients with any chronic liver disease (CLD). Patients experiencing chronic illness are several times more likely to experience depression than the general population. Symptoms include emotional suffering, loss of purpose, and impaired ability to function and complete daily activities.

Patients with CLDs are at risk for complications, comorbidities, and developing cirrhosis and hepatocellular carcinoma (HCC), which may result in the need for a liver transplant or death. The depressive symptoms and mental disorders that manifest in CLD patients greatly impact the trajectory of the chronic illness and the patient's ability to cope with the disease, resulting in a lower perceived quality of life.

This connection between liver disease and mental health is critical to understand. Depression in a PBC patient is not simply "in their head" — it is a real and measurable consequence of living with a chronic, unpredictable disease that affects nearly every aspect of daily life, from sleep to social interactions to the ability to work.

Fatigue: The Most Debilitating Symptom

Fatigue is the most reported symptom among PBC patients, and it can range from mild to completely debilitating. Importantly, fatigue is often independent of disease severity — even patients with early-stage PBC may experience intense fatigue. Fatigue can have detrimental effects on mental, physical, and social health by preventing individuals from participating in daily activities and interacting with others. This negative impact largely contributes to patients reporting a low self-perceived health-related quality of life.

The research data on fatigue in PBC is striking. A study that assessed 327 PBC patients over 7.2 years reported that 44% of patients experienced moderate to severe symptoms, with 25% experiencing mild to severe fatigue as measured using the PBC-40 survey. Increased fatigue was positively correlated with higher body mass index, itching, cirrhosis, and increased use of prescribed medications including antipruritic drugs and antidepressants. Patients diagnosed at a later stage of disease experienced a greater symptom burden, possibly due to a lack of earlier disease management.

Another study of 116 PBC patients reported that 99 patients experienced fatigue, and 50% of those patients described fatigue as one of the worst — if not the worst — symptom of their disease. When measured using the Fatigue Impact Scale (FIS) and Symptom Checklist-90 (SCL-90), PBC patients scored significantly higher than controls, indicating a large symptom burden.

Perhaps most tellingly, of the 116 total patients in that study, 52 scored above 10 on the Beck Depression Inventory, indicating the presence of depressive symptoms. While self-reported depressive symptoms are not the same as a clinician's formal diagnosis of depression, this study strongly suggests that fatigue and depressive symptoms are highly correlated in PBC patients.

A separate study monitoring fatigue and quality of life in 81 female PBC patients using the FIS and SF-36 surveys found that fatigue was a primary predictor of quality of life due to its impact on physical, social, emotional, and psychological factors.

The large UK-PBC cohort assessed symptoms in 2,002 PBC patients using the Hospital Anxiety and Depression Scale, Epworth Sleepiness Scale, and Orthostatic Grading Scale. Of the 1,203 patients who reported significant fatigue, 55% also reported significant cognitive symptoms, suggesting there may be a relationship between fatigue and cognitive defects (problems with thinking, memory, and concentration).

Many studies have found that fatigue in PBC is associated with depressive symptoms, poor cognitive health, and poor health-related quality of life. Fatigue can prevent patients from completing physical activity, interacting with friends and family, maintaining a normal sleep schedule, holding a job, and completing normal tasks. The social isolation that results only compounds the mental health burden.

Pruritus (Itching) and Sleep Disturbances

Pruritus, or itch, is a common and debilitating symptom in patients with chronic liver disease. As many as 60% to 70% of patients with PBC report experiencing pruritus. Like fatigue, itching can occur at any stage of PBC and is independent of disease severity. Although most patients describe their itching as mild, a significant proportion report severe pruritus that interferes with maintaining a sleep schedule and completing daily functions.

Pruritus is associated with fatigue, depression, and — in severe cases — may even be associated with suicidal ideation. This is a sobering reminder of how profoundly this symptom can affect mental health.

Most patients with chronic liver disease (60–80%) also experience sleep disorders such as insomnia, excessive daytime sleepiness (EDS), or difficulty staying asleep. A study of 48 female PBC patients and 48 female control subjects, monitored using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale, found that PBC patients spend 30 more minutes in bed at night than controls and experience significantly more sleep latency (the time it takes to fall asleep). PBC patients also perceive that they sleep for a significantly shorter amount of time than controls.

These sleep problems may be caused by disruption of the melatonin metabolism pathway (the liver partially regulates melatonin, the hormone that controls sleep-wake cycles) or by decreased hepatic blood flow and competition with bilirubin in the intrahepatic transport system. PBC patients often report that pruritus affects their ability to sleep — therefore, itching often coincides with excessive daytime sleepiness and other sleep disturbances.

Why Do Depression and Anxiety Occur in PBC? Possible Mechanisms

Depression and anxiety in PBC may have a multifactorial basis — meaning multiple factors likely contribute. Current scientific hypotheses point to three main possibilities:

1. Disrupted neurotransmitter synthesis
2. Changes in brain structure visible on imaging scans
3. Psychological distress directly resulting from the symptom burden of fatigue and pruritus

Neurotransmitter Synthesis: The Amino Acid Connection

A key 2001 study evaluated serum amino acid concentrations in 45 PBC patients at a European medical center, using 73 healthy individuals and 22 patients with untreated hepatitis C viral infections as control groups. The researchers sought to determine whether neurotransmitter synthesis is impaired in patients with cholestasis (reduced bile flow) by measuring blood levels of tyrosine, tryptophan, and branched-chain amino acids.

Tryptophan is of particular interest because it is the amino acid precursor to serotonin — the neurotransmitter that stabilizes mood and helps regulate appetite and sleep. The study found:

• Plasma tyrosine concentrations were inversely correlated with fatigue — meaning patients with lower tyrosine levels had worse fatigue
• Plasma tryptophan levels were significantly negatively correlated with the cognitive domain of fatigue as measured on the FFSS scale
• PBC patients with higher tyrosine levels than controls had lower fatigue scores
• Overall, lower levels of tyrosine and tryptophan were significantly associated with higher levels of fatigue and worse quality of life

Although this study did not directly assess depressive symptoms and anxiety in PBC patients, there is a well-established link between neurotransmitter levels and depression and anxiety. This research suggests that the liver's role in processing amino acids — the building blocks of mood-regulating neurotransmitters — may be directly relevant to the fatigue and emotional symptoms PBC patients experience.

A separate study evaluating the role of psychological factors in PBC-associated fatigue reported that the group of "high-fatigue" patients were significantly more likely to report depressive and anxious symptoms.

Brain Structure Changes

The symptom burden and mental health challenges associated with PBC may also result from physical changes in brain structure. A study of 20 female noncirrhotic PBC patients and 21 age-matched controls evaluated the relationship between symptom burden and changes in the brain's deep gray matter using resting-state functional magnetic resonance imaging (rsfMRI) and resting-state functional connectivity. The specific brain structures evaluated were the amygdala, hippocampus, thalamus, and putamen — structures that are essential for learning, memory, and processing emotions.

The results were significant: PBC patients exhibited reduced activity of the putamen in the basal ganglia on functional MRI. Other fMRI studies have also linked disruptions in the amygdala, hippocampus, basal ganglia, and thalamus of the limbic system with depression and altered connectivity in deep gray matter of the brain in PBC patients when compared to controls.

Another study of 14 pre-cirrhotic PBC patients and controls found a relationship between differences in the magnetization transfer ratios of the globus pallidus (a structure below the cortex near the putamen) and fatigue. Manganese, a mineral normally excreted through the bile ducts, has been implicated as a possible cause of fatigue in PBC. This suggests that when bile flow is impaired, manganese may accumulate in the brain and contribute to symptoms.

Self-Assessment vs. Clinical Diagnosis: An Important Distinction

One of the most important findings in this research area is the difference between self-reported depressive symptoms and a formal clinical diagnosis of depression. This distinction has major implications for how we understand mental health in PBC.

A German study conducted on 20 PBC patients and 20 age-matched control subjects reported that PBC patients were severely more affected by depressive symptoms and psychological symptoms as measured by the BDI and SCL-90 scales. Further analysis of the SCL-90 showed that PBC patients experienced significantly more somatization (physical symptoms caused by psychological distress), compulsive behavior, depressive symptoms, anxiety, aggressiveness, and other psychiatric symptoms.

However, a different study of 92 Dutch patients with either PBC or primary sclerosing cholangitis (PSC, another cholestatic liver disease) tells a more nuanced story. The researchers set out to verify whether the prevalence of depression in PBC was truly between 20% and 45%, as other studies had reported. They used multiple separate tools to measure depressive symptom severity and confirm diagnosis.

Here is what they found:

• Of the 55 PBC patients screened, 21 patients scored above 10 on the BDI scale, exceeding the cutoff for depression screening
• However, of those 21 patients, only 2 met the formal DSM-IV criteria for a depression diagnosis

This is a crucial finding. The researchers concluded that while the BDI, Hamilton Rating Scale for Depression, and CES-D questionnaires are each effective at measuring the severity of depressive symptoms, the DSM-IV is the tool used to clinically diagnose depressive disorder. Although PBC patients may experience increased depressive symptom burden, this does not automatically equate to a clinical diagnosis of depression.

The study concluded that the prevalence of formal depressive disorder is similar in PBC populations compared to the general population. The manifestation of depressive symptoms in PBC patients may result from the symptom burden of the disease itself — the fatigue, the itching, the sleep disruption, the social isolation — or may be unrelated to PBC altogether. This distinction matters because it suggests that effectively managing PBC symptoms may, in many cases, also improve mood and emotional well-being.

Liver Transplant and Mental Health in PBC

For patients with advanced PBC, liver transplantation is a life-saving option. The procedure is associated with excellent long-term survival: the 5-year survival rate is 80% and the 10-year survival rate is 70%. PBC may recur in the transplanted liver, but recurrence does not diminish long-term outcomes overall. Recurrent PBC is usually diagnosed via liver biopsy of the transplanted organ.

In a study of 785 PBC patients who underwent liver transplant across North America and Europe, PBC recurrence was observed in a subset of patients, yet long-term survival remained favorable. For patients experiencing severe symptom burden and mental health challenges in end-stage disease, transplant offers the possibility of dramatic improvement in quality of life, though the post-transplant period brings its own physical and emotional challenges.

Medications and Therapies for Depression and Anxiety in PBC

Managing mental health in PBC requires a comprehensive approach that addresses both the underlying liver disease and the psychological symptoms. Currently, the only FDA-approved therapies for PBC itself are ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), both of which reduce the risk of disease progression. However, patients may need additional support for their mental health symptoms.

A 2018 analysis of a UK PBC cohort of 1,177 patients identified between April 1974 and May 2007 provided important insights into antidepressant use in PBC:

• 7.3% of patients were diagnosed with depression prior to their PBC diagnosis
• 6.7% were diagnosed with depression after their PBC diagnosis
• 11.1% of patients took antidepressants before their PBC diagnosis
• 24.6% took antidepressants after their diagnosis

The study also found that PBC patients with depression had an increased risk of mortality compared to those without depression. This underscores how seriously mental health must be taken in PBC care.

Perhaps most encouragingly, after adjusting for UDCA use, gender, severity of depression, and alcohol intake, treatment with the antidepressant mirtazapine was correlated with a decreased risk of decompensated cirrhosis, need for liver transplant, and death. Mirtazapine is an atypical antidepressant that works on both central and peripheral networks, acting as an antagonist on norepinephrine, serotonin, and histamine receptors. This dual effect on mood and potentially on liver disease progression makes it a particularly interesting therapeutic option.

A separate study evaluated the effects of mirtazapine on autoimmune hepatitis (AIH), a chronic liver disease that can overlap with PBC. Researchers dosed mice with concanavalin A (Con A) to imitate human AIH. Mirtazapine reduced liver damage and significantly increased hepatic innate immune responses in the Con A-induced mice. While this is animal research, it suggests that mirtazapine may have direct beneficial effects on the liver itself, beyond its antidepressant properties.

Other medications that may be prescribed to PBC patients to help manage mental health and symptom burden include hydroxyzine (often used for itching and anxiety) and sertraline (an SSRI antidepressant).

Limitations of Current Research

It is important to understand the limitations of the research reviewed here. Many of the studies rely on self-assessment questionnaires, which are inherently subjective. A patient's mood on any given day, their understanding of the questions, and their willingness to report symptoms honestly can all affect results.

As discussed earlier, self-reported depressive symptoms do not always align with a formal clinical diagnosis of depression, as demonstrated by the Dutch study in which only 2 of 21 patients who screened positive on the BDI met DSM-IV criteria. This means some studies may overestimate the prevalence of clinical depression in PBC populations.

Additionally, many studies have relatively small sample sizes and predominantly female, Caucasian study populations, which reflects the demographics of PBC itself but may limit generalizability. Causal relationships between fatigue, neurotransmitter levels, brain changes, and depression cannot be definitively established from cross-sectional studies — we know these factors are associated, but we cannot always say which causes which.

Finally, the research on mirtazapine's potential liver benefits is largely based on animal models and retrospective cohort analyses. Prospective, randomized controlled trials are needed to confirm these findings before definitive treatment recommendations can be made.

Recommendations for Patients

Based on this review of the evidence, here are actionable recommendations for patients living with PBC:

1. Take your mental health seriously. If you are experiencing persistent sadness, loss of interest in activities, anxiety, or feelings of hopelessness, talk to your healthcare provider. Depression in PBC is associated with increased mortality, so it is not something to ignore.
2. Understand that your symptoms are real. Fatigue, itching, and sleep problems in PBC are physiological — they are linked to changes in neurotransmitter production and brain structure, not just psychological weakness. You are not imagining things.
3. Ask about the PBC-40 and other assessment tools. These validated questionnaires can help your doctor understand your symptom burden and track changes over time. Consider asking for a mental health screening at your regular hepatology appointments.
4. Discuss medication options with your hepatologist and psychiatrist. The research suggests that mirtazapine may offer dual benefits for mood and liver outcomes in some patients. Other antidepressants like sertraline and anti-itch medications like hydroxyzine may also help. Work with your care team to find the right combination.
5. Address sleep problems proactively. Since 60–80% of chronic liver disease patients experience sleep disturbances, talk to your doctor if you struggle with insomnia, daytime sleepiness, or poor sleep quality. Managing pruritus at night is especially important since itching often disrupts sleep.
6. Don't let fatigue isolate you. Fatigue is the most-reported symptom of PBC and can make social interaction and daily tasks feel impossible. Be honest with family and friends about your limitations, and seek support from PBC patient communities where others understand what you are going through.
7. Stay on your PBC medications. UDCA and OCA reduce disease progression risk, and effective management of the underlying liver disease is the foundation for improved quality of life.
8. Seek a mental health professional with experience in chronic illness. The psychological burden of living with a chronic disease is unique, and a therapist who specializes in chronic illness can help you develop coping strategies for the emotional challenges of PBC.

The bottom line is this: PBC affects the whole person, not just the liver. Fatigue, itching, sleep disturbances, depression, and anxiety are all part of the disease experience for many patients. The good news is that these symptoms are increasingly recognized by researchers and clinicians, and there are effective strategies to address them. If you are struggling, you are not alone — and help is available.

Frequently Asked Questions

I have PBC and feel depressed and anxious. Is this common, and could it be related to my liver disease?

Yes, depression and anxiety are common in chronic liver disease, including PBC. Many patients report depressive symptoms on self-assessment questionnaires. However, one study of 55 PBC patients found that only 2 of 21 who screened positive actually met formal DSM-IV criteria for depression. Your symptoms are real and can be linked to fatigue, itching, sleep problems, and even changes in brain chemistry.

What is the difference between self-reported depressive symptoms and a clinical diagnosis of depression in PBC?

Self-reported depressive symptoms come from questionnaires like the Beck Depression Inventory, where patients rate their own feelings. A clinical diagnosis uses formal criteria, such as DSM-IV, applied by a clinician. In one study of 55 PBC patients, 21 scored above the depression screening cutoff, but only 2 met formal diagnostic criteria. So symptom burden, not clinical depression, may explain many cases.

Can fatigue and itching in PBC really affect my mental health? How?

Yes, fatigue and itching are common and can be debilitating. They interfere with sleep, work, and social life, leading to isolation and distress. A study of 116 PBC patients found that 99 experienced fatigue, and 50% called it one of their worst symptoms. Pruritus can disrupt sleep and, in severe cases, has been associated with suicidal ideation.

Are there any medications that can help both my PBC and my depression or anxiety?

Yes, the antidepressant mirtazapine was associated with a decreased risk of decompensated cirrhosis, liver transplant need, and death in a 2018 UK cohort analysis of 1,177 PBC patients. Mirtazapine works on norepinephrine, serotonin, and histamine receptors. Other medications like sertraline (an SSRI) and hydroxyzine (for itching and anxiety) may also be used. Always discuss options with your hepatologist and psychiatrist.

I have trouble sleeping because of itching. Is poor sleep common in PBC, and what can I do?

Sleep disturbances are very common in chronic liver disease, affecting 60-80% of patients. A study of 48 female PBC patients found they took longer to fall asleep and perceived shorter sleep than controls. Pruritus often disrupts sleep, so managing itching at night is important. Talk to your doctor about strategies to improve sleep, as it can affect fatigue and mood.

Can liver transplant improve mental health and quality of life in PBC?

Liver transplantation is life-saving for advanced PBC, with 5-year survival of 80% and 10-year survival of 70%. It can dramatically improve quality of life, though the post-transplant period has its own challenges. PBC may recur in the transplanted liver, but recurrence does not diminish long-term outcomes overall. Discuss transplantation timing and mental health support with your care team.

What should I do if I feel depressed as a PBC patient? Should I mention it to my liver doctor?

Yes, mention it. Depression in PBC is associated with increased mortality, so it is not something to ignore. Ask for a mental health screening at your hepatology appointments. Tools like the PBC-40 can help quantify symptom burden. Consider seeing a therapist experienced with chronic illness and discuss medication options like mirtazapine with your doctor, as it may offer dual benefits for mood and liver outcomes.

Source Information

This patient-friendly article is based on the following peer-reviewed research:

Original Title: Anxiety and Depression in Patients with Primary Biliary Cholangitis: Current Insights and Impact on Quality of Life

Authors: Tarika Sivakumar and Kris V. Kowdley

Journal: Hepatic Medicine: Evidence and Research, 2021:13, pages 83–92

Published: 28 August 2021

DOI: 10.2147/HMER.S256692

Corresponding Author: Kris V. Kowdley, Liver Institute Northwest, Seattle, WA, USA

This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace professional medical advice. Always consult your healthcare provider about your specific medical condition and treatment options.